SABS (SAB Biotherapeutics) Insider Ownership: 15.64 % (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SABS SAB Biotherapeutics Inc SABS
26 GF Score
Price $3.70
! 2 Warning Signs
View Full Analysis

What is SAB Biotherapeutics Insider Ownership?

SAB Biotherapeutics SABS -2.12% 26 Insider Ownership is 15.64 % as of Aug. 21, 2026. GuruFocus rates SABS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, SAB Biotherapeutics's insider ownership is 15.64%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, SAB Biotherapeutics's Institutional Ownership is 91.52%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, SAB Biotherapeutics's Float Percentage Of Total Shares Outstanding is 96.88%.

SAB Biotherapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for SAB Biotherapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SAB Biotherapeutics Insider Ownership Chart

SAB Biotherapeutics Historical Data

The historical data trend for SAB Biotherapeutics can be seen below:

2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 22.23 22.23 21.42 21.42 21.42 21.42 21.45 15.64 15.64 15.64
SABS
26GF Score
SAB Biotherapeutics Inc SABS
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SAB Biotherapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 15.64 % mean?
SAB Biotherapeutics (SABS) has a Insider Ownership of 15.64 % as of Aug. 21, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on SAB Biotherapeutics and its competitors.
Is SAB Biotherapeutics' Insider Ownership too high?
SAB Biotherapeutics' current Insider Ownership is 15.64 %. Overall, SAB Biotherapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' Insider Ownership compare to SLGL and BCYC?
SAB Biotherapeutics' Insider Ownership of 15.64 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on SAB Biotherapeutics and its competitors. SAB Biotherapeutics's current Insider Ownership is 15.64 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current Insider Ownership of 15.64 %. The current Insider Ownership is 15.64 %. SAB Biotherapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current Insider Ownership is 15.64 % as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SAB Biotherapeutics Business Description

Address 777 West 41st Street, Suite 401, Miami Beach, FL, USA, 33140
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
26GF Score

Get the complete analysis for SABS

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.70
Price